The writer is chief executive of Sanofi
We are entering a new phase of Covid-19 as interim data, first from Pfizer and BioNTech, and then Moderna, show promise of a safe and effective vaccine. More candidates are expected to follow — Sanofi has two vaccines in trials. One, a collaboration with GSK, is based on our flu vaccine and data from phase 1 and 2 studies will come shortly. The second is a messenger RNA vaccine similar in approach to Pfizer and Moderna. But, having a vaccine is only one facet in the complicated war to contain the virus.
Distribution is perhaps the biggest hurdle. Vaccines are not interchangeable and ensuring that individuals get two doses, if required, of the same vaccine is critical. There may also be issues with safeguarding potency. Moderna’s and Pfizer’s vaccines need to be stored at minus 20C and about minus 70C respectively, and used within five or 30 days of being refrigerated. Pharmaceutical companies are rushing to develop transportable cold storage containers and logistics companies are building freezer farms. Mass vaccination clinics, such as the UK’s repurposed Nightingale hospitals, could help distribution in cities.